As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD. Belantamab mafodotin provides a ...
Key End Points for Providers to Consider With New Multiple Myeloma Therapies: Hearn Jay Cho, MD, PhD
As novel multiple myeloma therapies enter the relapsed and refractory treatment landscape, safety is a key consideration, says Hearn Jay Cho, MD, PhD. The FDA approval of belantamab mafodotin (Blenrep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results